People | June 23, 2022
Piramal Pharma Solutions appoints Herve Berdou as COO
Brings 25 years of global operations and supply chain experience to Piramal
Brings 25 years of global operations and supply chain experience to Piramal
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Subscribe To Our Newsletter & Stay Updated
